Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04413279 · ClinicalTrials.gov registry record · Phase 4
Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
A Phase 4 study of Dry Eye Syndromes, sponsored by Eye Surgeons of Indiana.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04413279: Completed Phase 4 study of Dry Eye Syndromes, sponsored by Eye Surgeons of Indiana.
NCT04413279 is a Phase 4 study of Dry Eye Syndromes that has completed, run by Eye Surgeons of Indiana. The registered enrollment target is 20 participants, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04413279, a Phase 4 study of Dry Eye Syndromes, has completed, sponsored by Eye Surgeons of Indiana.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.
Primary Outcome
As measured on a grading scale 1 to 4 and graded by the physician
Conditions Studied
Interventions
- PROCEDURE LipiFlow Thermal Pulsation
- DRUG Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Study Locations (1)
Indiana
- Eye Surgeons of Indiana - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 4 |
What the finished NCT04413279 record still lists
NCT04413279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 413-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which LipiFlow Thermal Pulsation is the first listed.
NCT04413279 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04413279 about?
NCT04413279 is a clinical study titled "Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease". To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.
What is the current status of trial NCT04413279?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2020-08-01. Estimated completion is 2021-07-01.
What conditions does trial NCT04413279 study?
This clinical trial studies the following conditions: Dry Eye Syndromes.
What interventions are being tested in trial NCT04413279?
The interventions under investigation include: LipiFlow Thermal Pulsation (PROCEDURE), Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation (DRUG).
Who is sponsoring clinical trial NCT04413279?
This trial is sponsored by Eye Surgeons of Indiana, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04413279 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04413279's enrollment target sits among peer trials
20 16th of 17 higher than 2 of 17 other Dry Eye Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACCURATE Study for Subjects With Dry Eyes
COMPLETED · Phase 4
-
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
COMPLETED · Phase 4
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
-
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
COMPLETED · NA
-
TrueTear in Sjogren's Disease Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI